Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
National standards for diabetes self-management education.

Diabetes care

Mensing C, Boucher J, Cypress M, Weinger K, Mulcahy K, Barta P, Hosey G, Kopher W, Lasichak A, Lamb B, Mangan M, Norman J, Tanja J, Yauk L, Wisdom K, Adams C.
PMID: 12502650
Diabetes Care. 2003 Jan;26:S149-56. doi: 10.2337/diacare.26.2007.s149.

No abstract available.

A non-toxic approach for treatment of breast cancer and its metastases: capecitabine enhanced photodynamic therapy in a murine breast tumor model.

Journal of cancer metastasis and treatment

Anand S, Yasinchak A, Bullock T, Govande M, Maytin EV.
PMID: 30740528
J Cancer Metastasis Treat. 2019;5. doi: 10.20517/2394-4722.2018.98. Epub 2019 Jan 24.

AIM: Breast cancer (BCA) in women is a leading cause of mortality and morbidity; distant metastases occur in ~40% of cases. Here, as an alternative to ionizing radiation therapy and chemotherapy and their associated side effects, we explored a...

2018 American Society of Consultant Pharmacists Annual Meeting & Exhibition.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists

Bridgeman M, Prete D, Rolston N, Abazia D, Sturgill M, Finn L, Summers D, Marvanova M, Henkel P, Thompson J, Dewey M, Friesner D, Marvanova M, Alessi C, Cuellar L, Yamagishi L, O'Neil C, Erickson O, Mazzei K, Kamal K, Early N, Bainter B, Hanson L, Schmitz E, Loomis A, Norberto M, Hume A, Meyer M, Batra R, Likar D, Enguidanos S, Liu C, Kotansky B, Fisher A, Ruby CM, Pruskowski J, Karim SNA, Yong BSW, Alessi C, Cuellar L, Slattum P, Crouse E, Delafuente J, Donohoe K, Ogbonna K, Peron E, Powers K, Price E, Zimmerman K, Rahim S, Gendron T, Slattum P, Donohoe K, Cho C, Zimmerman K, Crouse E, Peron E, Powers K, Price E, Slattum P, Donohoe K, Elliott L, Minter C, Morin M, Marshall L, Stevens G, Cordaro C, Hill M, Nagy K, Kroustos KR, Sobota KF, Mahan R, Bailey T, Ioannou K, Mansour D, Thompson T, Chatellier K, Schwenk A, Ruby C, Chen TS, Li S, James M, Spilios M, Leschak A, Levine A, Forgette S, Oluigbo N, Szollosi D, Avalime D, Weaver SB, Maneno M, Ettienne E, Yi JY, Hart L, Gray S, Ozalas S, Miller K, Dave R, Bork J, Emmelhainz J, Adams K, Postolski J, Willoughby M, Feldman E, Braham K, Miller C, Barbagallo D, Seabury R, Noviasky J, Alessi C, Cuellar L, Dabhi J, Bartlett D, Le T, Simoni-Wastila L, Kuzucan A, Simoni-Wastila L, Le T, Park S, Simoni-Wastila L, Le T, Park S, Choi M, Simoni-Wastila L, Park S, Le T, Choi M, Simoni-Wastila L, Khokhar B, Choi M, Le T, Simoni-Wastila L, Brody P, Hejna M, Mason J, Graham M, Micceri J, Lypska R, Quinn B, Wilson H, Wahler R, Aloyo M, Tomm V, Hill A, Obringer A, Butterfoss K, Blak J, Balcer R, Boza J, Foster A, Shafique E, Kleven C, Wigle P, Brown B, Alessi C, Cuellar L, Meyer K, Mobley-Bukstein W, Singh H, Perez E, Mira AE, Kuehner W, Czechowski L, Cook H, Brandt N, Parson J, Fornaro R, Brandt N, Claeys K, Zarowitz B, Mansour D, McFadden C, Simpkins S, Ojowa F, Klutts A, Holmes S, Smith E, Cornman JR, Doran K, Resnick B, Brandt N, Umeozulu C, Williams A, Brandt N, Hennawi G, Thomas D, Gerber DK, Meyer K, Sharma K, Cooke C, Howard A, Chater R, Vogler A, Brandt N, Kennett-Hayes K, Elliott L, Engelbert J, Hargrave E, Bambico C, Patel K, Warriner C, Slattum P, Desai NR, Rowan CG, Alvarez P, Fogli J, Toto RD, Desai NR, Alvarez P, Fogli J, Reed P, Owens MK, Greden JF, Rothschild AJ, Zandy S, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechairo B, Parikh S, Donohue J, Feldman G, Sethi S, Barnes C, Pendyala S, Bourdet D, Ferguson G, Barnes C, Pendyala S, Crater G, Fogli J, Mayo M, Gross C, Miyawa J, Ono R, Woods S, Garza D, Panov N, Fogli J, Moran E, Sabesan V, Wertman J, Ngim K.
PMID: 30322434
Consult Pharm. 2017 Oct 01;33(10):572-608.

Poster abstracts are evaluated based on the following criteria: significance of the problem to healthy aging or medication management; innovativeness of ideas, methods, and/or approach; methodological rigor of methods and approach; presentation of finding; implications identified for future research,...

Painless Photodynamic Therapy Triggers Innate and Adaptive Immune Responses in a Murine Model of UV-induced Squamous Skin Pre-cancer.

Photochemistry and photobiology

Anand S, Govande M, Yasinchak A, Heusinkveld L, Shakya S, Fairchild RL, Maytin EV.
PMID: 33113217
Photochem Photobiol. 2021 May;97(3):607-617. doi: 10.1111/php.13350. Epub 2020 Nov 22.

Painless photodynamic therapy (p-PDT), which involves application of photosensitizer and immediate exposure to light to treat actinic keratosis (AK) in patients, causes negligible pain on the day of treatment but leads to delayed inflammation and effective lesion clearance (Kaw...

Validity of FFQ Estimates of Total Sugars, Added Sugars, Sucrose and Fructose Compared to Repeated 24-h Recalls in Adventist Health Study-2 Participants.

Nutrients

Peralta M, Heskey C, Shavlik D, Knutsen S, Mashchak A, Jaceldo-Siegl K, Fraser GE, Orlich MJ.
PMID: 34836407
Nutrients. 2021 Nov 19;13(11). doi: 10.3390/nu13114152.

Sugar intake is a potentially important aspect of diet which has not previously been validated in the Adventist Health Study-2 (AHS-2). We sought to validate the food frequency questionnaire (FFQ) measurement of total sugars, added sugars, sucrose, and fructose...

Painless versus conventional photodynamic therapy for treatment of actinic keratosis: Comparison of cell death and immune response in a murine model.

Proceedings of SPIE--the International Society for Optical Engineering

Anand S, Yasinchak A, Govande M, Shakya S, Maytin EV.
PMID: 33790491
Proc SPIE Int Soc Opt Eng. 2019 Feb;10860. doi: 10.1117/12.2511646. Epub 2019 Feb 28.

Aminolevulinic acid based photodynamic therapy (ALA-PDT) is a popular and efficacious treatment for actinic keratosis (AK). However, standard PDT can elicit stinging pain during illumination, and hence is not always favored by patients. In a new regimen called metronomic...

Outcomes of Pre-Early Treatment for Retinopathy of Prematurity (Pre-ETROP).

Clinical ophthalmology (Auckland, N.Z.)

Titawattanakul Y, Kulvichit K, Varadisai A, Mavichak A.
PMID: 33116390
Clin Ophthalmol. 2020 Oct 16;14:3393-3397. doi: 10.2147/OPTH.S268997. eCollection 2020.

INTRODUCTION: The earlier treat stage 3 ROP is more likely to achieve better outcomes.PRIMARY PURPOSE: To study the unfavorable outcomes and regression after pre-early treatment for ROP.SECONDARY PURPOSE: To evaluate the progression and recurrence of ROP requiring retreatment after...

Showing 1 to 7 of 7 entries